Genomic evaluation in patients with diffuse large B cell lymphoma
- Conditions
- Neoplasms
- Registration Number
- KCT0003963
- Lead Sponsor
- Samsung Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- All
- Target Recruitment
- 200
1.Patients with histopathologically confirmed DLBCL
2.Patients diagnosed with DLBCL who relapsed or were refractory to first-line treatment with rituximab-based immunotherapy
3.Patients available for genomic analysis of tissues both at diagnosis (paraffin-embedded and stored) and at relapse (paraffin-embedded)
4.Patients aged =18 years
5.Patients who provide written informed consent for participation in the prospective cohort study
6.Patients who provide written informed consent to peripheral blood collection and genetic testing of human tissues
1.Patients who have no lymphoid malignancy, e.g. myeloid leukemia
2.Patients with any of the following lymphoid malignancies:
1)Plasma cell dyscrasia, amyloidosis
2)Hodgkin lymphoma
3)Subtypes of B cell non-Hodgkin lymphoma, other than DLBCL
4)T or NK cell non-Hodgkin lymphoma
5)Other diseases in the WHO classification of lymphoid malignancies
3.Patients who have experienced a relapse before
4.Patients with insufficient or no tissue sample at diagnosis for genomic analysis
5.Patients who do not understand or provide written informed consent
6.Patients who do not provide written informed consent to blood collection and genetic testing
Study & Design
- Study Type
- Observational Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To evaluate response and survival following a salvage therapy depending on the genomic sequencing results, and to investigate the prognostic or predictive value of genomic mutation.
- Secondary Outcome Measures
Name Time Method To investigate the response to salvage chemotherapy and survival outcome.;To determine the association between gene mutation, treatment response and prognosis.